Microbot Medical Inc. announced the successful completion of its GLP pivotal pre-clinical study, done under the guidelines of FDA-required levels of planning, controlling, monitoring, and reporting, using a porcine model. The study was conducted by three leading interventional radiologists that utilized the LIBERTY Endovascular Robotic Surgical System to perform a total of 96 robotic navigations. Target vessels with surrounding tissue were examined and evaluated microscopically after they were subjected to procedures using a range of commercially available intravascular catheterization devices controlled and manipulated via the LIBERTY Endov vascular Robotic Surgical System.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.933 USD | +1.05% | -3.61% | -42.99% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-42.99% | 13.29M | |
+26.17% | 44.96B | |
-0.80% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+9.51% | 26.08B | |
-21.48% | 19.03B | |
+6.16% | 12.75B | |
+27.77% | 12.06B | |
-3.38% | 11.75B |
- Stock Market
- Equities
- MBOT Stock
- News Microbot Medical Inc.
- Microbot Medical Announces the Successful Completion of its GLP Pivotal Pre-Clinical Study